NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology · Netherlands

Last price 20.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.48B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere...